TyG-BMI and METS-IR best parameters for predicting hypertension risk in diabetics: Study

Written By :  Medha Baranwal
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2022-10-18 05:30 GMT   |   Update On 2022-10-18 08:28 GMT
Advertisement

Germany: A recent study published in Diabetology & Metabolic Syndrome has shown triglyceride-glucose index with body mass index (TyG-BMI) and metabolic score for IR (METS-IR) to be independent risk factors for the prevalence of hypertension. Both the parameters (TyG-BMI and METS-IR) had good predictive value for the prevalence of hypertension, and TyG-BMI was superior to METS-IR.

Hypertension is one of the leading causes of disability-adjusted life years worldwide and is a critical public health challenge. Its prevalence is expected to increase globally, particularly in developing countries. The number of people affected by hypertension will likely increase to 1.56 billion by 2025. In this regard, it is essential to early identify specific populations at potential risk of hypertension development to lower mortality and disability associated with hypertension.

Various studies have examined the association between insulin resistance (IR) surrogates and hypertension risk. However, there is a lack of ambiguity on whether the differences exist between different IR surrogates and the risk of hypertension. Therefore, Siwei Chen, Department of Cardiovascular Medicine, The Third Hospital of Nanchang, Nanchang, Jiangxi, China, and colleagues aimed to investigate the association of four IR surrogates (TyG index, TyG-BMI, triglycerides/high-density lipoprotein cholesterol ratio (TG/HDL-c), and METS-IR)) with the prevalence of hypertension.

For this purpose, the researchers performed a cross-sectional study with a total of 117,056 participants. Data were extracted from a database that included all medical records of participants who received a health check-up from 2010 to 2016. IR surrogates were classified into quartiles as continuous variables. The relation between different IR surrogate levels and the prevalence of hypertension was estimated using multivariate logistic regression.

For further evaluating the relationship between baseline characteristics and the four IR surrogates, and prevalence of hypertension, and the importance of every single variable for the prevalence of hypertension.

The study demonstrated the following findings:

· Multivariate logistic regression analysis showed that METS-IR and TyG-BMI were independent risk factors for the prevalence of hypertension that increased significantly with increasing METS-IR and TyG-BMI.

· The area under the TyG-BMI curve (AUC) was 0.681, and the cut-off value was 199.5, with respective sensitivity and specificity of 65.57% and 61.18%.

· The area under the METS-IR curve (AUC) was 0.679, and the cut-off value was 33.61, with respective sensitivity and specificity of 69.67% and 56.67%.

· TyG-BMI was the most critical predictor of hypertension prevalence among these four IR surrogates and related variables, with a significance of 34%. The results before and after multiple imputations were similar.

"TyG-BMI and METS-IR (among the IR surrogates described) were independent risk factors for the prevalence of hypertension," the researchers wrote in their conclusion. 

"TyG-BMI and METS-IR had acceptable predictive value for the prevalence of hypertension, and TyG-BMI had the upper hand over METS-IR."

Reference:

Cheng, W., Kong, F. & Chen, S. Comparison of the predictive value of four insulin resistance surrogates for the prevalence of hypertension: a population-based study. Diabetol Metab Syndr 14, 137 (2022). https://doi.org/10.1186/s13098-022-00907-9

Tags:    
Article Source : Diabetology & Metabolic Syndrome

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News